{"success":true,"data":{"pressRelease":{"id":"25600","rtpr_id":"nGNX3rHQG0","ticker":"FEED","exchange":"NASDAQ","all_tickers":["FEED"],"title":"ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals","author":"Globe Newswire","published_at":"2026-05-07T12:07:00.106Z","article_body":"TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc\n(https://www.globenewswire.com/Tracker?data=qr9KEAh_8ulbEPZ7GkfN6I9vTqQFMan1OvTrNxujC6-q9VYHUnHI_ioq0zBt-xsXWNjd2V_DHx_h05G06pjyd27exyyqqW7jLutMGiWTYVY=).\n(NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a\ncommercial-stage medical device company focused on real-time guided bedside\nfeeding tube placement, today announced a three-year purchasing agreement\nrenewal with the Group Purchasing Organization (“GPO”) for one of the\nlargest non-profit health systems in the United States, operating over 90\nhospitals across 17 states.\n\nThe renewal ensures that hospitals and care sites within the network can\naccess the ENvue™ Navigation Platform through established contracting\npathways, without the need for individual procurement processes at the\nfacility level.\n\nContracted access within a health system of this scale represents a\nsignificant commercial infrastructure advantage. Rather than navigating\nfacility-by-facility value analysis committee approvals - a process that can\ntake months - any participating hospital within the network can move directly\nto adoption. The three-year term locks that position through 2028, providing\nENvue with a long-duration contracting foundation across a large and\ngeographically distributed hospital network.\n\n\"This renewal is an important commercial milestone for ENvue. We believe that\nhaving established access within a network of more than 90 hospitals in the\nU.S. means our technology is one clinical decision away from adoption at any\nparticipating facility. It reflects confidence in our platform, removes a\ncritical friction point for customers, and gives us a durable foundation from\nwhich to drive broader utilization across the network,\" stated Doron Besser,\nMD, Chief Executive Officer of ENvue Medical.\n\nENvue Medical remains focused on converting contracted access into active\nadoption, expanding its installed base within large health system networks,\nand building long-term recurring commercial relationships with leading\nhealthcare institutions across the United States.\n\nAbout ENvue Medical, Inc.\nENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company\nspecializing in the advancement of intelligent, non-invasive solutions for\nenteral care across clinical and home care settings. Headquartered in Tyler,\nTexas, with research and development in Tel-Aviv and Nesher, Israel, the\nCompany focuses on two distinct technology platforms:\n* ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc.,\nwith offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a\nminimally invasive electromagnetic navigation system intended to assist\nclinicians in placing feeding tubes into the gastrointestinal tract. FDA\n510(k) cleared for adult use, ENvue provides real-time bedside visualization\nof tube movement and supports informed decision-making during the placement\nprocedure. Future platform expansion may include pediatric and vascular access\napplications.\n* ENvue Medical aims to advance standards in non-invasive therapy and\nminimally invasive navigation, with a commitment to patient safety, clinical\nusability, and technology innovation across a range of healthcare\nenvironments.\n* Acoustic-based therapeutic technologies, including PainShield® and\nUroShield®, which utilize proprietary low-intensity surface acoustic wave\n(SAW) technology. These devices are intended for use in home or care settings\nand are designed to treat pain, reduce bacterial colonization, and disrupt\nbiofilms.\nForward-Looking Statements\nThis press release contains “forward-looking statements.” Such statements\nmay be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential,” or\nsimilar words. These forward-looking statements include, but are not limited\nto: statements regarding the adoption and implementation of ENvue Medical’s\nplatforms, anticipated commercial expansion, growth, scalability, and\nimplementation of ENvue Medical’s products, the success of ENvue’s\nprograms, market interest in the Company’s technology, and future\nexpectations for strategic growth. Forward-looking statements are not\nguarantees of future performance, are based on certain assumptions, and are\nsubject to various known and unknown risks and uncertainties, many of which\nare beyond the Company’s control and cannot be predicted or quantified;\nconsequently, actual results may differ materially from those expressed or\nimplied by such forward-looking statements. Such risks and uncertainties\ninclude, without limitation: (i) market acceptance of the Company’s existing\nand new products; (ii) clinical performance and operational outcomes; (iii)\ndelays or complications in product implementation; (iv) intense competition in\nthe medical device industry; (v) product liability or performance issues; (vi)\nlimitations in manufacturing or supply chain capabilities; (vii) reimbursement\nlimitations; (viii) intellectual property protection; (ix) healthcare\nregulatory changes in the U.S. and abroad; and (x) the need for additional\ncapital. More detailed information about the Company and the risk factors that\nmay affect the realization of forward-looking statements is set forth in the\nCompany’s filings with the Securities and Exchange Commission (“SEC”),\nincluding the Company’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, and Current Reports on Form 8-K. Investors and security holders are\nurged to read these documents free of charge at: www.sec.gov. The Company\nassumes no obligation to publicly update or revise its forward-looking\nstatements as a result of new information, future events, or otherwise, except\nas required by law.\n\nInvestor Contact:\nKCSA Strategic Communications\nValter Pinto, Managing Director\nPH: (212) 896-1254\nenvue@kcsa.com\n\nMedia Contact:\nKCSA Strategic Communications\nMichaela Fawcett, Senior Account Director\nPH: (978) 995-4683\nenvue@kcsa.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0a97028-a7c3-4dd6-a13f-a55e43617883)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3rHQG0","title":"ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals","author":"Globe Newswire","ticker":"FEED","created":"2026-05-07T12:07:00.106Z","tickers":["FEED"],"exchange":"NASDAQ","article_body":"TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc\n(https://www.globenewswire.com/Tracker?data=qr9KEAh_8ulbEPZ7GkfN6I9vTqQFMan1OvTrNxujC6-q9VYHUnHI_ioq0zBt-xsXWNjd2V_DHx_h05G06pjyd27exyyqqW7jLutMGiWTYVY=).\n(NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a\ncommercial-stage medical device company focused on real-time guided bedside\nfeeding tube placement, today announced a three-year purchasing agreement\nrenewal with the Group Purchasing Organization (“GPO”) for one of the\nlargest non-profit health systems in the United States, operating over 90\nhospitals across 17 states.\n\nThe renewal ensures that hospitals and care sites within the network can\naccess the ENvue™ Navigation Platform through established contracting\npathways, without the need for individual procurement processes at the\nfacility level.\n\nContracted access within a health system of this scale represents a\nsignificant commercial infrastructure advantage. Rather than navigating\nfacility-by-facility value analysis committee approvals - a process that can\ntake months - any participating hospital within the network can move directly\nto adoption. The three-year term locks that position through 2028, providing\nENvue with a long-duration contracting foundation across a large and\ngeographically distributed hospital network.\n\n\"This renewal is an important commercial milestone for ENvue. We believe that\nhaving established access within a network of more than 90 hospitals in the\nU.S. means our technology is one clinical decision away from adoption at any\nparticipating facility. It reflects confidence in our platform, removes a\ncritical friction point for customers, and gives us a durable foundation from\nwhich to drive broader utilization across the network,\" stated Doron Besser,\nMD, Chief Executive Officer of ENvue Medical.\n\nENvue Medical remains focused on converting contracted access into active\nadoption, expanding its installed base within large health system networks,\nand building long-term recurring commercial relationships with leading\nhealthcare institutions across the United States.\n\nAbout ENvue Medical, Inc.\nENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company\nspecializing in the advancement of intelligent, non-invasive solutions for\nenteral care across clinical and home care settings. Headquartered in Tyler,\nTexas, with research and development in Tel-Aviv and Nesher, Israel, the\nCompany focuses on two distinct technology platforms:\n* ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc.,\nwith offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a\nminimally invasive electromagnetic navigation system intended to assist\nclinicians in placing feeding tubes into the gastrointestinal tract. FDA\n510(k) cleared for adult use, ENvue provides real-time bedside visualization\nof tube movement and supports informed decision-making during the placement\nprocedure. Future platform expansion may include pediatric and vascular access\napplications.\n* ENvue Medical aims to advance standards in non-invasive therapy and\nminimally invasive navigation, with a commitment to patient safety, clinical\nusability, and technology innovation across a range of healthcare\nenvironments.\n* Acoustic-based therapeutic technologies, including PainShield® and\nUroShield®, which utilize proprietary low-intensity surface acoustic wave\n(SAW) technology. These devices are intended for use in home or care settings\nand are designed to treat pain, reduce bacterial colonization, and disrupt\nbiofilms.\nForward-Looking Statements\nThis press release contains “forward-looking statements.” Such statements\nmay be preceded by the words “intends,” “may,” “will,”\n“plans,” “expects,” “anticipates,” “projects,” “predicts,”\n“estimates,” “aims,” “believes,” “hopes,” “potential,” or\nsimilar words. These forward-looking statements include, but are not limited\nto: statements regarding the adoption and implementation of ENvue Medical’s\nplatforms, anticipated commercial expansion, growth, scalability, and\nimplementation of ENvue Medical’s products, the success of ENvue’s\nprograms, market interest in the Company’s technology, and future\nexpectations for strategic growth. Forward-looking statements are not\nguarantees of future performance, are based on certain assumptions, and are\nsubject to various known and unknown risks and uncertainties, many of which\nare beyond the Company’s control and cannot be predicted or quantified;\nconsequently, actual results may differ materially from those expressed or\nimplied by such forward-looking statements. Such risks and uncertainties\ninclude, without limitation: (i) market acceptance of the Company’s existing\nand new products; (ii) clinical performance and operational outcomes; (iii)\ndelays or complications in product implementation; (iv) intense competition in\nthe medical device industry; (v) product liability or performance issues; (vi)\nlimitations in manufacturing or supply chain capabilities; (vii) reimbursement\nlimitations; (viii) intellectual property protection; (ix) healthcare\nregulatory changes in the U.S. and abroad; and (x) the need for additional\ncapital. More detailed information about the Company and the risk factors that\nmay affect the realization of forward-looking statements is set forth in the\nCompany’s filings with the Securities and Exchange Commission (“SEC”),\nincluding the Company’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, and Current Reports on Form 8-K. Investors and security holders are\nurged to read these documents free of charge at: www.sec.gov. The Company\nassumes no obligation to publicly update or revise its forward-looking\nstatements as a result of new information, future events, or otherwise, except\nas required by law.\n\nInvestor Contact:\nKCSA Strategic Communications\nValter Pinto, Managing Director\nPH: (212) 896-1254\nenvue@kcsa.com\n\nMedia Contact:\nKCSA Strategic Communications\nMichaela Fawcett, Senior Account Director\nPH: (978) 995-4683\nenvue@kcsa.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e0a97028-a7c3-4dd6-a13f-a55e43617883)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-07T12:07:00.151452057Z","server_sent_at_ms":1778155620151},"received_at":"2026-05-07T12:07:00.224Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}